| CAM01 |
10798 |
Pilates In Multiple Sclerosis: A Systematic Review and Meta Analysis of Biochemical, Psychological, and Physical Outcomes |
| CAM02 |
11066 |
Adherence and Its Correlates from a Pilot Randomized Controlled Trial of Physical Activity Behavioral Intervention In People Newly Diagnosed with Multiple Sclerosis |
| CAM03 |
11061 |
Diet Quality In a Large Sample of People with Multiple Sclerosis |
| CAM04 |
10716 |
‘You Just Feel Alive’: Understanding Perceived Quality of Life Among Women Dancing with Multiple Sclerosis |
| CSS01 |
10576 |
Living the Experience – African American and Multiple Sclerosis: A Case Study |
| CSS02 |
10756 |
An Unsolved Case of Mogad: Hindsight Is 20/20 In 2025 |
| CSS03 |
10760 |
Hemophagocytic Lymphohistiocytosis Secondary to Chronic Babesiosis In a Patient Receiving Ocrelizumab for Multiple Sclerosis |
| CSS04 |
10818 |
A Rare Presentation of Overlapping Demyelinating Syndrome: Anti-NMDA Receptor Encephalitis and Multiple Sclerosis |
| CSS05 |
10819 |
Atypical PRES: A Mimicker of Demyelinating Disease |
| CSS06 |
10820 |
Recognizing Coexisting Myelitis Pathologies: Post-Infectious Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Accompanying West Nile Virus Myelitis |
| CSS07 |
10846 |
Dual B-cell Targeting across Disease States: Concurrent BTK Inhibition and Anti-CD20 Therapy In Relapsing Multiple Sclerosis with Chronic Lymphocytic Leukemia |
| CSS08 |
10850 |
Chronic Enterovirus Encephalitis In Two Patients with Multiple Sclerosis Treated with B-cell Depleting Therapy |
| CSS09 |
10862 |
Management of Refractory Marburg Variant Multiple Sclerosis with Cyclophosphamide |
| CSS10 |
10879 |
Progressive Multifocal Leukoencephalopathy In a Patient with Multiple Sclerosis Treated with Ocrelizumab: A Case Report |
| CSS11 |
10920 |
Progressive Longitudinally Extensive Myelopathy Due to an MT–ND6 Mutation: A Mitochondrial Mimic of Inflammatory Myelitis |
| CSS12 |
11012 |
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder Presenting As Optic Neuritis In an 83-Year-Old Male: A Case Report |
| CSS13 |
11031 |
Multiple Cranial Neuropathies Following BCMA CAR T-cell Therapy: A Case Series |
| CSS14 |
11036 |
Anti-Glycine Receptor Related Paraneoplastic Stiff-Person Syndrome Associated with Refractory Hodgkin’s Lymphoma |
| CSS15 |
11041 |
Pain Management Interventions within Lifestyle Redesign® Occupational Therapy Treatment: A Case Study of an Adult with Multiple Sclerosis |
| CSS16 |
11057 |
Primary Cns Lymphoma after Repeated Nondiagnostic Brain Biopsies Showing Only Inflammatory Changes |
| CSS17 |
11067 |
Paradoxical Development of Primary Cns Lymphoma during Anti-CD20 Therapy for Multiple Sclerosis |
| CSS18 |
11082 |
Breakthrough Disease Activity In Multiple Sclerosis Patients Treated with Anti-CD20 Therapies: A Real-World Retrospective Case Series |
| CSS19 |
11097 |
An Unusual Duo: Tandem Occurrence of Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease |
| CSS20 |
11098 |
Seizures As the First Clinical Manifestation of Pediatric Onset Multiple Sclerosis: A Case Report |
| CSS21 |
11121 |
Transient MRI Abnormalities Following Epstein-Barr Virus Encephalitis |
| CSS23 |
11128 |
Relapse of AQP4-IgG–Positive Neuromyelitis Optica Spectrum Disorder Following Initiation of Ravulizumab |
| CSS24 |
11134 |
Hemorrhagic Vasculitis In a Patient with Multiple Sclerosis Receiving Fingolimod |
| CSS25 |
11132 |
Incidences of Low-Titer Mog Antibody In Patients with Multiple Sclerosis and Neuromyelitis Optica – Case Report & Literature Review |
| CSS27 |
11171 |
Spinal Cord Lesions As an Atypical Presentation of Cadasil: A Case Initially Diagnosed As Multiple Sclerosis |
| CSS29 |
11184 |
Cns Demyelination In a Patient with Systemic Sarcoidosis Treated with Adalimumab. |
| CSS30 |
11186 |
Breakthrough AQP4-Positive Nmo on Ravulizumab: Implications of Incomplete Complement Inhibition and Therapeutic Switching |
| DMT07 |
10849 |
Ocrelizumab and Rituximab Comparison In the Treatment of Multiple Sclerosis |
| DMT08 |
10929 |
From Order to Infusion In Multiple Sclerosis: Identifying Modifiable Barriers to Timely Treatment |
| DMT09 |
10930 |
Treatment Preferences and Real-World Dmt Selection Among Newly Diagnosed Multiple Sclerosis Patients |
| DMT10 |
10843 |
Effect of Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor, on Patient-Reported Outcomes (PRO) In Progressive MS: Data from Phase 2 Calliper Trial |
| DMT11 |
10995 |
Safety and Tolerability of Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor: Data from Phase 2 Calliper Trial |
| DMT12 |
11084 |
Real-World Transition to Ublituximab from Prior Anti-CD20 Treatment In the Phase 4 Enable Study |
| DMT13 |
10966 |
Less Chair, More Care: Patient-Reported Outcomes with In-Clinic Subcutaneous Ocrelizumab |
| DMT14 |
10869 |
Effectiveness and Safety of Switching to Cladribine Tablets In US Patients with RMS Experiencing High Disease Activity or Disease Breakthrough Despite Current Dmt Use |
| DMT15 |
10788 |
Efficacy and Safety of Remibrutinib after Switching from Ocrelizumab In Participants with Relapsing Multiple Sclerosis: RESHAPE Study Design |
| DMT16 |
10938 |
Analysis of CD20-Directed Cytolytic Antibody Treatment Switches to Ocrelizumab and Hyaluronidase In Patients with Multiple Sclerosis (MS) |
| DMT17 |
10974 |
Mitigating Infection Risk In B-cell Depletion Therapy: A Multi-Tiered Surveillance Protocol for Multiple Sclerosis Patients |
| DMT18 |
11083 |
Real-World Study of Ocrelizumab and Other Disease-Modifying Therapy Utilization and Disease Activity from Preconception through Postpartum in Women With MS |
| DMT19 |
11090 |
Treatment Patterns of Ocrelizumab Subcutaneous: An Early Look Into Utilization in a Medicare Population With Multiple Sclerosis |
| DMT20 |
11096 |
Real-World Impact of Discontinuing Ocrelizumab on Healthcare Resource Utilization and Cost Among Older Adult Patients With Multiple Sclerosis in the United States |
| DMT21 |
11149 |
Developing a Pathway for Immediate Access to Ofatumumab for Persons with Multiple Sclerosis at High Risk of Relapse: Kesimpta In Hand (KIH) |
| DMT22 |
10992 |
Preliminary Baseline Characteristics and Early Follow-up In the COAST Study: Anti-CD20 to Ozanimod Sequencing Trial |
| DMT23 |
10670 |
Comparative Analysis of Disease-Modifying Therapies (DMTs) on Neurodegeneration, Brain Age Acceleration, and Disease Progression In Multiple Sclerosis |
| DMT24 |
10592 |
Effect of Cladribine Tablets on CSF Immune Cell Subsets In Patients with Relapsing Multiple Sclerosis (CLOCK-MS study) |
| DMT25 |
10883 |
Acapella: Real-World Experience with Ocrelizumab, 9-Year Data |
| DMT26 |
10888 |
Incomplete B-cell Repletion Suppression In Patients on Ocrelizumab: Does Switching to Ublituximab Make a Difference? |
| DMT27 |
10815 |
Update on the Randomized BEAT-MS Trial Comparing Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis |
| DMT28 |
10936 |
Impact of Proximity to MS Clinic and Infusion Clinics on Disease-Modifying Therapy: Prescribing Patterns In Multiple Sclerosis |
| DMT29 |
11072 |
Efficacy and Safety of Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results of the FENhance 1 and 2 Studies |
| DMT30 |
10988 |
Relationship between Cognitive Function and Brain Volume Outcomes In Patients with Relapsing Multiple Sclerosis In the phase 3b Enlighten Study: 3-Year Results |
| DMT31 |
10626 |
Individual Patient Data Meta-Analysis and Network Meta-Analysis of Comorbidities, Disease Modifying Therapies, and Adverse Outcomes In Persons with Multiple Sclerosis |
| DMT33 |
10951 |
Infection and Relapse Outcomes In People with MS Transitioning from Standard Interval Dosed Anti-CD20 Therapies to Fumarates or to Extended Interval Dosed Anti-CD20s |
| DMT34 |
10963 |
Association between Socioeconomic Characteristics and Treatment Outcomes With Ocrelizumab in the CHIMES Trial of Black and Hispanic People With Multiple Sclerosis |
| DMT35 |
10972 |
High- or Moderate-Efficacy Treatment Sequence and Patterns Among People with Relapsing-Remitting Multiple Sclerosis In the United States: A Retrospective cohort study |
| DMT36 |
11130 |
Real-World Causes and Outcomes of Natalizumab Treatment Delays: A Single Center Retrospective Review |
| DMT37 |
10958 |
Real-World Changes In Cognitive Function with Ozanimod for Relapsing-Remitting Multiple Sclerosis In the Prospective Ozean Study In Germany: 3-Year Results |
| DMT38 |
10989 |
Real-World Disability Progression In Ozanimod-Treated Participants with Relapsing-Remitting Multiple Sclerosis: Results of the Prospective, Noninterventional Ozean Study |
| DMT39 |
10990 |
Clinical Effectiveness and Safety of Ozanimod after Dmt Switch for Relapsing-Remitting Multiple Sclerosis In the Prospective Noninterventional Ozean Study: 3-Year Results |
| DMT40 |
11189 |
Ocrevus Vs Kesimpta In the Treatment of Relapsing Remitting Multiple Sclerosis |
| DMT41 |
11103 |
Indirect Treatment Comparison of Brain Volume Loss with Tolebrutinib Versus Other Therapies In Relapsing Multiple Sclerosis: A Network Meta-Analysis |
| DMT42 |
10876 |
Do We Really Need Steroids? Real-World Safety of Steroid-Free Ocrelizumab and Ublituximab Infusions |
| DMT43 |
10882 |
What Happens to IgG after Nearly a Decade of Ocrelizumab? Acapella Nine-Year Data |
| DMT44 |
10935 |
Subgroup Analysis of the Phase 3 Tolebrutinib HERCULES Trial: Disability Accumulation Outcomes in North American Participants |
| DMT45 |
11078 |
Evaluation of Ublituximab Infusion Tolerability: Analysis of Data Following the Ultimate phase 3 Studies |
| DMT46 |
10810 |
Pregnancy and Infant Outcomes In Women with Relapsing Multiple Sclerosis Following Exposure to Ofatumumab: Latest Evidence from the Prim Study |
| DMT47 |
11032 |
Evaluating the Presence and Concentration of Briumvi In Breast Milk (PROVIDE): An Interim Report |
| DMT48 |
11080 |
No Evidence of Disease Activity on Intravenous or Subcutaneous Ocrelizumab in Treatment-Naive Relapsing Multiple Sclerosis in the OPERA (10 Yrs) and OCARINA II (2 Yrs) Trials |
| DMT49 |
11009 |
Real-World Patient Safety and Experience Trends for Anti-CD20 Home Infusion – a 120 Week Review |
| DMT50 |
10758 |
Humoral and Cellular Immune Responses to COVID-19 Vaccination across Disease-Modifying Therapies In a Decentralized MS Cohort |
| DMT51 |
11116 |
A Review of the Current Landscape of Disease-Modifying Therapy Continuation, De-Escalation, and Discontinuation In Older Adults with Multiple Sclerosis |
| DMT52 |
10844 |
Cladribine Holds Its Weight: Comparable Lymphocyte Dynamics In People with Multiple Sclerosis Weighing Above and below 110 Kg |
| DMT53 |
10923 |
Safety of Cladribine Tablets In the Treatment of People with Multiple Sclerosis: 2025 Post-Approval Safety Update |
| DMT54 |
10807 |
Ozanimod-Associated Lymphopenia In Relapsing Multiple Sclerosis: Incidence, Association with Infection, and Impacts of Extended-Interval Dosing |
| DMT55 |
10673 |
Tolebrutinib Administration with Food: Clinical Trial Evidence and Implications for Dosing Guidelines |
| DMT56 |
10917 |
Blood Levels of Immune Cells, Immunoglobulins, and Platelets in the Phase 3 HERCULES and GEMINI Trials of Tolebrutinib in nrSPMS and RMS |
| DMT57 |
10600 |
Subcutaneous Administration of Frexalimab In Relapsing Multiple Sclerosis and Non-Relapsing Secondary Progressive Multiple Sclerosis: Design of the phase 3 Frexcite Trial |
| DMT58 |
10522 |
Optimization of Meningococcal Vaccination for Myasthenia Gravis (MG) and Neuromyelitis Optica Spectrum Disorders (NMOSD) Patients Receiving Complement Inhibitors (CIs) |
| EPI07 |
10622 |
The Impact of COVID-19 Infection and Vaccination on Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients: A Literature Review. |
| EPI08 |
10707 |
The Impact of COVID-19 Infection and Vaccination on Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD): A Literature Review. |
| EPI09 |
10703 |
A Metabolomics-Derived Body Mass Index Identifies Heterogeneity In Neurodegeneration Among Individuals with Progressive Multiple Sclerosis |
| EPI10 |
10937 |
Exploring the Feasibility of Integrating Genetic Data into a Patient-Reported Multiple Sclerosis Registry: The Narcoms Experience |
| EPI11 |
10956 |
Vedolizumab Exposure and the Prevalence of Multiple Sclerosis In Inflammatory Bowel Disease: A Large Real-World Analysis |
| EPI12 |
11177 |
Features of Late-Onset Multiple Sclerosis (LOMS) In a South Texas Population: A Single-Center Study |
| EPI13 |
11122 |
Optical Coherence Tomography Abnormalities across Autoimmune and Non-Autoimmune Neurologic Disorders: A Retrospective Etiology-Based Analysis |
| FAM01 |
10896 |
Financial and Mental Health Burden on Caregivers of Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) In the United States |
| FAM02 |
11148 |
Building Hope and Resilience through Connection: A Family Retreat Model for Pediatric MS and Nmo |
| FAM03 |
11150 |
Four Days a Year, Lasting Impact over the Last 18 Years: Building Hope and Community for Families Affected By Pediatric MS and Nmo |
| FAM04 |
11147 |
Sleep In Caregivers of People with Multiple Sclerosis: A Scoping Review |
| IIS01 |
11123 |
A Canadian MS Nurses’ Network (CMSNN) Collaboration to Develop Nursing Care Plans for MS, Nmosd and Mogad |
| IIS02 |
11175 |
Telecommunications Improve Access to Multiple Sclerosis Research: Participant Perspectives |
| IIS03 |
11170 |
A Randomized Trial of Mobile App Symptom Tracker for Relapse Detection In Multiple Sclerosis |
| IMG06 |
10672 |
Accelerated Brain Aging and Volume Loss In Multiple Sclerosis: A Cross-Sectional MRI Study |
| IMG07 |
11109 |
Brain-Age and Cognition In Multiple Sclerosis: Evidence for Improved Predictive Power of Brain-Age Compared to Conventional Structural Brain Metrics |
| MDC01 |
10808 |
The Neurology Workforce In American Medicine: Physician, Physician Associate, and Nurse Practitioner |
| MDC02 |
10924 |
Mapping the Multiple Sclerosis Care Journey: Integrating Lived Experience and Clinician Insight to Drive Implementation through the Multiple Sclerosis Implementation Network |
| MDC03 |
10981 |
Patient-Reported Outcomes Following a Multidisciplinary Patient Education Program for People with Multiple Sclerosis |
| MDC04 |
11049 |
Coordinated Multidisciplinary Evaluation Improves Rehabilitation Service Utilization In People with Multiple Sclerosis |
| MDC05 |
11114 |
Impact of a Multidisciplinary Bowel and Bladder Program Deployed In a Real-World Outpatient Care Setting for People with Multiple Sclerosis. |
| MDC06 |
11127 |
The Clock Starts at Discharge: Reducing Delays In Multiple Sclerosis Patient Care |
| MDC07 |
11185 |
Impact of a Focused Perimenopause Care Program on Clinical Outcomes In Women with Multiple Sclerosis: An EHR-Based Study |
| MDC08 |
11115 |
Intensive, Multidisciplinary Rehabilitation Program Improves Personalized Goal Outcomes In People Multiple Sclerosis |
| MDC09 |
10851 |
Dietitian Utilization and Multiple Sclerosis Outcomes: A Cross-Sectional Analysis of the Narcoms Research Registry |
| MOC01 |
10652 |
Bridging the Knowledge-to-Action Gap In MS Rehabilitation: A Clinical Decision-Making Toolbox for Outpatient Practice |
| MOC02 |
10654 |
The Psychosocial Impact of a Non-Structured Peer-Led Support Group on People with Multiple Sclerosis |
| MOC03 |
10727 |
Accessibility of Paraclinical Testing for MS Diagnosis within the Veterans Health Administration |
| MOC04 |
10750 |
Implementation of a Multidisciplinary Transition of Care Program In a Pediatric Neuroimmunology Clinic |
| MOC05 |
10766 |
Make Your Voice Count a Focused Patient Activation Initiative Developed By Can Do MS In Collaboration with Novartis |
| MOC06 |
10795 |
Optimizing Multiple Sclerosis Care: The Impact of Neurology Pharmacists In Dmt Management |
| MOC07 |
10866 |
Evaluation of the Impact of a Diagnosis of Multiple Sclerosis on Family Planning: A Survey-Based Study |
| MOC08 |
10895 |
Latent Class Analysis of Treatment Preferences Among Adults With Aquaporin-4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States |
| MOC09 |
10898 |
A Quantitative Measurement for Coproduction Value Creation In Complex, Chronic, and Costly (3C) Conditions: Phase III of the CO-VALUE Study In Multiple Sclerosis |
| MOC10 |
10970 |
Advancing Scientific Publication Among Multiple Sclerosis Nurses through Mentorship: An International Consensus |
| MOC11 |
11007 |
Performing Lumbar Punctures In Hospital Based Neuroimmunology Clinic |
| MOC12 |
11014 |
Beyond the Clinic: Providing Credible Educational Resources for Persons with Multiple Sclerosis via Social Media |
| MOC13 |
11028 |
Real-World Tolerability of Oral Versus Intravenous Steroid Premedication for Anti-CD20 Infusions In Multiple Sclerosis |
| MOC14 |
11062 |
What People with MS Need from Digital Health: Information, Trust, and the Promise of AI |
| MOC15 |
11077 |
Reconsidering the Diagnostic Value of Patient-Reported Subjective Data In the Care and Treatment of Multiple Sclerosis |
| MOC16 |
11079 |
Establishing Patient and Family Partner Engagement at the Barlo MS Centre to Support Quality Improvement and Patient-Facing Resources |
| MOC17 |
11140 |
Accesslink Reduces Time to First Dose of Ofatumumab for People Living with Multiple Sclerosis (PLwMS) |
| MOC18 |
11154 |
Describing Pharmacy Technician Roles In Multiple Sclerosis Collaborative Care at Yale New Haven Health |
| NDM01 |
10978 |
Health and Societal Benefits of Earlier Diagnosis and Access to Immunotherapies In Anti–Aquaporin-4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder In the US |
| NDM02 |
10726 |
Identifying N-(alkyl)-4-Arylpiperidine As a Novel Anti-Inflammatory Compound on Attenuating Neuroinflammation and Disease Severity In MS Preclinical Models |
| NDM03 |
10836 |
Long-Term Immunity to Influenza and Sars Cov-2 In Vaccinated and Non-Vaccinated MS Patients Treated with Ocrelizumab and Ofatumumab: 2-Year Longibims Results |
| NDM04 |
10871 |
Effectiveness and Safety of Ocrelizumab in Patients With Pediatric- Vs Young Adult–Onset Multiple Sclerosis: An MSBase Registry Matched Cohort Analysis |
| NDM05 |
11163 |
The Final Diagnoses In Adult Patients with Low Titer Mog Antibody |
| NDM06 |
10829 |
Single-Cell Analysis of Genetically Perturbed FADS1 Activity Revealed the Causal Effect of Omega-3 Fatty Acid Metabolism on MS Severity |
| NIB01 |
10759 |
Real-World Utilization of a Novel Multi-Analyte Blood-Based Biomarker Panel, the Octave® Msda Test In Clinical Practice across the United States |
| NIB02 |
10987 |
Measuring Biological Effects of Dmts In Clinical Practice: A Large-Scale Analysis of the Octave® Msda Test Moderate-Score Cohort |
| NIB03 |
10642 |
Gene Expression Signatures Associated with Prior Rituximab Treatment in Patients with AQP4-Ab+ Neuromyelitis Optica Spectrum Disorder (NMOSD) in the CHAMPION-NMOSD Trial |
| NIB04 |
10767 |
Frexadigital AI Substudy: AI-Based Smartphone Video Assessments of Motor Function In RMS and Non-Relapsing SPMS Population |
| NIB05 |
10867 |
Gut Microbiome Analysis across a Multiple Sclerosis Cohort Does Not Predict Long-Term Disease Progression Assessed By EDSS |
| NIB06 |
10890 |
Using the Octave® Msda Test to Identify Differences In Disease Activity and Panel Biomarkers between Natalizumab and Anti-CD20 Therapies |
| NIB07 |
11125 |
Do microRNA Profiles Correlate with Frailty Status In People with Multiple Sclerosis? |
| NIB08 |
11095 |
Distinct Metabolomic Signatures Following Dietary Interventions In Relapsing Multiple Sclerosis: Evidence from the Edq-MS Trial |
| NPP01 |
10561 |
Spectrum of Clinical and Paraclinical Features of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Among a Pediatric and Adult Case Series. |
| NPP02 |
10842 |
Increased Expression of Vimentin and FABP7 In Astrocytes In Multiple Sclerosis Brains |
| NPP03 |
11099 |
Understanding the Impact and Burden of Menopause on Multiple Sclerosis Through a Targeted Literature Review |
| PGM01 |
10840 |
Virtual Training to Advance Pain Management Education In MS Care for Professionals and Persons Living with MS |
| PGM02 |
11069 |
Time to Multiple Sclerosis Diagnosis: A Comparison of Wisconsin and National Trends |
| PGM03 |
11094 |
Trends of Physical Therapy Services for Plwms Using Prisma Health In the Midlands Area, South Carolina. |
| PSY07 |
11000 |
Is Physical Activity Associated with Anxiety and with Depression Symptoms In People with Multiple Sclerosis Who Have Analogue Generalized Anxiety Disorder? |
| PSY08 |
10854 |
What Drives Change In Cognitive Speed? Predictors of One-Year Symbol Digit Modalities Test Performance In Multiple Sclerosis |
| PSY09 |
10997 |
Components of the Health Belief Model Associated with Physical and Mental Health Outcomes for Patients with Multiple Sclerosis |
| PSY10 |
11013 |
Investigation of the Impact of Area Deprivation Index on the Relationship between Stigma and Cognitive Functioning In Multiple Sclerosis Patients |
| PSY11 |
11042 |
Barriers and Facilitators to Participation In Home, School, and Community Activities for Children with Multiple Sclerosis: A Qualitative Study. |
| PSY12 |
11129 |
Frailty, Social Support, and Mental Health In People with Multiple Sclerosis: A Mixed Methods Analysis |
| QOL01 |
10873 |
AI Assisted Evaluation of Outcomes Supports That Newly Diagnosed Programs Have Positive Benefits for People Living with MS. |
| QOL02 |
11020 |
Patient-Reported Outcomes In Treatment-Naïve Patients with Very Early Relapsing-Remitting Multiple Sclerosis Treated with Ofatumumab: Results from the Agnos Study |
| QOL03 |
10786 |
Implementation of a Lifestyle Medicine Program to Improve Quality of Life In Multiple Sclerosis |
| QOL04 |
10996 |
Quality of Life Outcomes for People with Multiple Sclerosis Participating In a Day Wellness Program over Four Years: Pre and Post COVID-19 Pandemic |
| QOL05 |
11118 |
Evaluating the Economic Value of Monoclonal Antibodies for AQP4+ Nmosd In the US Using Attack-Free Survival over a 5-Year Horizon |
| QOL06 |
11138 |
What Aspects of Treatment Are Important to People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)? a Qualitative Study |
| QOL07 |
11152 |
Treatment Patterns Among Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD): A Real-World Evidence Study |
| QOL08 |
11159 |
Comparative Efficacy of Inebilizumab Versus Rituximab for Attack Prevention In Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: A Matching-Adjusted Indirect Comparison Analysis |
| QOL09 |
10733 |
Therapeutic Uncertainty In Early Multiple Sclerosis: Factors Associated with Decisional Conflict Regarding Treatment Choice |
| QOL10 |
10597 |
Impact of Urinary Symptoms and Satisfaction with Nursing Care on Quality of Life In Patients with Multiple Sclerosis: A Cross-Sectional Study |
| QOL11 |
10794 |
Understanding Intersectional Considerations of Gender and Women with MS In Canada; Preliminary Insights from Newfoundland and Labrador, Canada |
| QOL12 |
11105 |
Perceived Social Support Impacts Self-Efficacy In People with Multiple Sclerosis |
| QOL13 |
10832 |
Pilot Testing a Virtual Nurse-Led Purpose-Building Intervention In Women with Multiple Sclerosis |
| QOL14 |
11190 |
Predictors and Functional Impact of Demyelination-Related Movement Disorders In Multiple Sclerosis |
| QOL15 |
11033 |
Evaluating the Effectiveness of a Mobile Mindfulness Application on Quality of Life In Patients with Multiple Sclerosis |
| QOL16 |
10537 |
How Will Climate Change Impact Severity and Incidence of Multiple Sclerosis (MS)? |
| QOL17 |
11126 |
Shaping Tomorrow Together – the Multiple Sclerosis (MS) Externally-Led Patient-Focused Drug Development Initiative[ |
| QOL18 |
10826 |
Patient Characteristics, Health Outcomes, and Treatment Patterns In Nonrelapsing Secondary Progressive Multiple Sclerosis: A Retrospective cohort study In the US |
| QOL19 |
11141 |
Benefits of Women’s Health Consultations: Breastfeeding Outcomes In Multiple Sclerosis |
| QOL20 |
11086 |
Quality of Life In Patients with Multiple Sclerosis In New Jersey: A Promis-Based Assessment |
| QOL21 |
10907 |
Patient Perspectives on Portal Messaging In Multiple Sclerosis Care: Insights and Opportunities |
| QOL22 |
11100 |
Prognostic Factors for Progression Independent of Relapse Activity In Relapsing Multiple Sclerosis: A Systematic Review and Meta-Analysis |
| QOL23 |
11019 |
Evaluation of Sleep Quality In Multiple Sclerosis Patients |
| QOL24 |
10814 |
Age-Dependent Associations between Targetable Symptoms and Wellness In Women with Early Multiple Sclerosis |
| QOL25 |
10569 |
GLP-1 Receptor Agonist Use Associated with Greater Physical Activity and Improved Patient-Reported Outcomes In Multiple Sclerosis: A Single-Site Retrospective cohort study |
| REH07 |
10668 |
Proactive Pelvic Floor Rehabilitation for Multiple Sclerosis during Pregnancy & Postpartum |
| REH08 |
10762 |
Detecting Improvements with Intraindividual Variability Versus Mean Performances: A Secondary Analysis of a Compensatory Cognitive Intervention |
| REH09 |
10774 |
Improving Processing Speed through Better Sleep: The Impact of CBT-I In Women with Multiple Sclerosis |
| REH10 |
10791 |
Impact of Eccentric Training on Fatigue In Multiple Sclerosis |
| REH11 |
10885 |
Automated Gait Assessment Reveals Improvements In Gait In Adults with MS Using a Functional Electrical Stimulation Sleeve |
| REH12 |
10942 |
Physiological-Perceptual Fall Risk Discordance before and after Walking Rehabilitation In Multiple Sclerosis |
| REH13 |
10944 |
Task Specific Vs Fitness Based Home Exercise Programs for MS |
| REH14 |
10952 |
The Role of Vascular Function In the Oxygen Cost of Walking In Multiple Sclerosis |
| REH15 |
11169 |
Understanding Dropout and Engagement In Multiple Sclerosis Cognitive Rehabilitation Studies |
| REH16 |
10730 |
Functional Cognition In Multiple Sclerosis: The Role of Occupational Therapy In Managing Cognitive Deficits Affecting Instrumental Activities of Daily Living |
| REH17 |
11182 |
Dalfampridine Modifies Cognitive-Motor Interaction Pattern In People with MS |
| REH18 |
11179 |
Investigating the Effect of Dalfampridine on Foot Clearance Fatigability In People with Multiple Sclerosis |
| REH19 |
10902 |
Building the Bridge to Real-World Gait In Multiple Sclerosis through Sensory-Challenged Laboratory Walking |
| RTH01 |
10529 |
Complement Inhibition As Rescue Therapy after Inebilizumab Failure in Hispanic Patients with Nmosd: A Single-Center Retrospective Analysis |
| RTH02 |
10889 |
Real-World Clinical Outcomes With Eculizumab and Ravulizumab in AQP4-Ab+ Neuromyelitis Optica Spectrum Disorder (NMOSD): Results From the Global NMO SPOTLIGHT Registry |
| SCR01 |
10971 |
Artificial Intelligence Literacy and Self-Care Behaviors In People with Multiple Sclerosis: A Cross-Sectional Study |
| SYM01 |
10540 |
Identifying Challenges to Mscopilot® ‘s Integration into Multiple Sclerosis Standard Clinical Practice: Methodology of MS-Flower, an Ongoing U.S. Multicenter Pilot Study |
| SYM02 |
10845 |
Fine Motor Function As a Potential Indicator of Cognitive Status In Multiple Sclerosis: A Cross-Sectional Study |
| SYM03 |
10940 |
Polypharmacy In Multiple Sclerosis: A Cross-Sectional Analysis and Development of a Clinical Assessment Tool |
| SYM04 |
11151 |
Sleep Experience Among People with Multiple Sclerosis: A Qualitative Exploration |
